Collegium’s Q3 2026 Playbook: ADHD Portfolio Delivers While Guidance Holds Steady

Ticker COLL + EPS, earnings surprise, EPS consensus, revenue forecast — a quick peek at what the numbers may imply for the next few quarters and why investors should care about the company’s evolving lineup.

Executive snapshot

Collegium Pharmaceutical, Inc. — trading under the ticker COLL — reported third-quarter 2026 results that underscore the durability of its ADHD portfolio, even as it continues to integrate AZSTARYS into a post-acquisition structure. Net revenues reached $216.3 million, a 3% year-over-year increase, as the company reaffirmed its full-year 2026 guidance. The quarter also highlighted a notable contribution from JORNAY PM, which generated a quarterly net revenue of $51.9 million, up 24% year over year, and AZSTARYS net revenue of $26.5 million in the first full quarter under Collegium ownership. Pain portfolio revenues stood at $138.0 million, painting a picture of a diversified, mid-to-high single-digit growth mix even as ADHD remains the flagship engine.

Financial highlights

Net revenue: $216.3 million, up 3% YoY.
JORNAY PM net revenue: $51.9 million, up 24% YoY.
AZSTARYS net revenue: $26.5 million in the 2026 Quarter (first full quarter under Collegium ownership).
Pain portfolio net revenues: $138.0 million.
Adjusted EBITDA: $121.6 million.
ADHD franchise contribution: now more than 36% of total revenue.
Guidance: full-year 2026 financial targets reaffirmed.
Capital allocation: announced a $50 million accelerated share repurchase to be completed before year-end.
Operational note: conference call scheduled for today at 8:00 a.m. ET.

Note to readers: while the press release emphasizes revenue and EBITDA strength, it does not disclose quarterly earnings per share (EPS) in the release. Investors often look to EPS consensus and potential earnings surprises in subsequent updates for a fuller per-share profitability view. The absence of an explicit EPS figure means the market will watch how the revenue mix translates into per-share metrics over time, alongside the reaffirmed revenue forecast for 2026.

Operational highlights and product momentum

The company continues to leverage its ADHD portfolio, with JORNAY PM as a key driver of growth. The 24% YoY rise in JORNAY PM net revenue reflects expanded prescriber adoption and stronger demand, particularly as Collegium completes the integration of AZSTARYS. AZSTARYS’ first full quarter under Collegium ownership delivered $26.5 million in net revenue, signaling the acquired asset is beginning to contribute meaningfully to the quarterly mix.

Collegium’s pain portfolio remains a robust revenue stream, generating $138.0 million in net revenues for the quarter. The company frames this as the foundation that supports ongoing ADHD expansion and business development, alongside capital allocation strategies aimed at optimizing shareholder value.

Strategic initiatives

Two operational initiatives stood out in the quarter: Start Talking ADHD, an online resource hub designed to assist patients and families in navigating conversations with healthcare providers and schools, and a multi-year partnership with Boston Legacy FC, Boston’s professional women’s soccer club. The former signals a patient-centric approach to expanding access and literacy around ADHD, while the latter signals a community-anchored branding effort that Scrooge-like CFOs would approve if it translates into broader brand recognition and patient outreach.

Management commentary and capital discipline

Vikram Karnani, President and CEO, emphasized the continued demand across the ADHD portfolio and highlighted AZSTARYS’ performance under Collegium’s ownership as a “meaningful improvement” versus prior annual prescription declines. Colleen Tupper, CFO, reiterated confidence in full-year 2026 guidance and underscored disciplined capital allocation, including debt management and opportunistic shareholder returns. The company also disclosed a $50 million accelerated share repurchase program, expected to close before year-end, signaling a willingness to deploy excess cash to support equity value.

Market implications for Collegium and peers

Collegium’s quarter reinforces a broader narrative: the ADHD drug ecosystem remains a meaningful growth engine for specialty pharma, particularly when a company can blend asset integration with targeted commercial investments. For COLL, the mix shift toward JORNAY PM and AZSTARYS—coupled with favorable revenue mix dynamics (ADHD contributing over one-third of revenue)—could improve operating leverage if gross margins hold steady and SG&A scales sublinearly with revenue.

From a sector perspective, peers eyeing ADHD portfolios may take note of Collegium’s approach to portfolio management, launch execution, and patient engagement programs. The Start Talking ADHD initiative and the Boston Legacy FC partnership point to a broader trend: pharma companies blending patient access programs with community partnerships to strengthen brand affinity and prescriber engagement. If this model proves scalable, we might see more niche players leaning into higher-value, companion-like programs to offset generic competition and payer pressure.

Outlook, risks, and a word on valuation

The reaffirmed 2026 guidance provides a degree of comfort to investors who favor predictability in mid-sized specialty pharma names. The accelerated share repurchase signals confidence in cash generation and a willingness to return capital, which could buoy the stock in the near term even if tax or debt considerations loom larger later in the cycle.

Risks to watch include: sustained growth in JORNAY PM and AZSTARYS versus expanding competition in ADHD therapies, potential shifts in payer dynamics, and the pace at which AZSTARYS is integrated into Collegium’s go-to-market engine. A lot rides on the durability of the ADHD franchise relative to other portfolios and on how effectively the company can translate revenue gains into per-share profitability (EPS) and EPS consensus upgrades over time. The market will also be attentive to how the company executes the share repurchase and whether capital returns will crowd out investments in pipeline or early-stage opportunities.

Bottom line

Collegium’s Q3 2026 results depict a company whose ADHD portfolio—anchored by JORNAY PM and AZSTARYS—continues to scale, supported by cost-conscious capital management and strategic community initiatives. The reaffirmed revenue forecast and the announced share repurchase reflect a management team confident in its cash-generation profile and long-term growth trajectory. For investors watching COLL, the near-term narrative is about translating this revenue momentum into durable earnings power, a task that will hinge on how well the AZSTARYS integration sticks and whether the ADHD business sustains its outsize share of the company’s revenue mix.

Appendix: quick reference metrics